EGFR-TP53 共突变晚期非小细胞肺癌研究进展
摘要
关键词
全文:
PDF参考
Zheng R S. et al. Cancer incidence and mortality in China, 2022. Zhonghua Zhong Liu Za Zhi 2024,46:221-231.
Freddie, Bray, Jacques, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA: a cancer journal for clinicians, 2018.
Li X M, Li W F, Lin J T, et al. Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial[J]. Clinical lung cancer, 2021(2):22.
Sabapathy K, Lane D P. Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others[J]. Nat Rev Clin Oncol, 2018(15):13-30.
Passaro A, Attili I, Rappa A, et al. Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations[J].Cancers, 2021,13(9).
Pezzuto F. The significance of co-mutations in EGFR-mutated non-small cell lung cancer: Optimizing the efficacy of targeted therapies?[J]. Lung Cancer, 2023,181,107249.
Marei H E. p53 signaling in cancer progression and therapy[J]. Cancer Cell Int 2021,21,703.
Gomes A S, Ramos H, Inga A, et al. Structural and Drug Targeting Insights on Mutant p53[J]. Cancers (Basel), 2021:13.
Blakely C M, Watkins T B K, Wu W, et al. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers[J]. Nature Genetics, 2017.
Castellanos E, Feld E, Horn L. Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non–Small Cell Lung Cancer[J]. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer, 2016,12(4).
Ferrara M G. Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors[J]. Crit Rev Oncol Hematol, 2023,184:103929.
Qin K, Hou H, Liang Y, et al. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: A meta-analysis[J]. BMC Cancer, 2020,20(1).
Gu W. The prognosis of TP53 and EGFR co-mutation in patients with advanced lung adenocarcinoma and intracranial metastasis treated with EGFR-TKISs[J]. Front Oncol, 2023,13:1288468.
Papadimitrakopoulou V A, Mok T S, Han J Y, et al. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis[J]. Annals of Oncology, 2020.
Boutelle A M, Attardi L D. p53 and Tumor Suppression: It Takes a Network[J]. Trends Cell Biol, 2021,31:298-310.
Chen, Nan, Xianping, et al. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation[J]. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer, 2015,10(6):910-923.
Offin, Michael Chan, Joseph M. Tenet, MeganRizvi, Hira A.Shen, RonglaiRiely, Gregory J.Rekhtman, NatashaDaneshbod, YahyaQuintanal-Villalonga, AlvaroPenson, AlexanderHellmann, Matthew D.Arcila, Maria E.Ladanyi, MarcPe’er, DanaKris, Mark G.Rudin, Charles M.Yu, Helena A.Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes[J]. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer, 2019,14(10).
Rho J K, Choi Y J, Ryoo B Y, et al. p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer[J]. Cancer Research, 2007, 67(3):1163-1169.
Jung S, Kim D H, Choi Y J, et al. Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer[J]. Nature Publishing Group, 2021(1).
Raoof S, Mulford I J, Frisco-Cabanos H, et al. Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer[J]. Oncogene, 2019,38(37):1.
Cao J, Gu J J, Liang Y, et al. Evaluate the Prognosis ofMYC/TP53Comutation in Chinese Patients with EGFR-Positive Advanced NSCLC Using Next-Generation Sequencing: A Retrospective Study[J]. Technology in Cancer Research & Treatment, 2022,21(21):11120-11127.
Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma[J].Diabetes care, 2022(5):45.
Hosomi Y, Morita S, Sugawara S, et al. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study[J]. J Clin Oncol, 2020(2).
Hou X. Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non-Small Cell Lung Cancer in Patients With Brain Metastases: The GAP BRAIN Open-Label, Randomized, Multicenter, Phase 3 Study. JAMA Netw Open 6, 2023:e2255050.
方文峰,张力.2023年度非小细胞肺癌免疫治疗研究进展[J].肿瘤综合治疗电子杂志,2024,10(1):25-32.
Liu S Y, Geng S, Shi N, et al. Survival Prediction of Patients Treated With Immune Checkpoint Inhibitors via KRAS/TP53/EGFR-Single Gene Mutation[J]. Frontiers in Pharmacology, 2022,13.
Li A M, Amélie Boichard, Kurzrock R. Mutated TP53 is a marker of increased VEGF expression: analysis of 7,525 pan-cancer tissues[J]. Cancer biology & therapy, 2019,21(1):1-6.
Nishio M RELAY. Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome. Clin Lung Cancer, 2023,24:415-428.
Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study[J]. BMC Cancer, 2023,23(1).
Hu M, Cheng H, Yang Y, et al. Valproic acid increased the efficacy of EGFR TKIs on EGFR/TP53 co‐mutated lung cancers and downregulated mutant‐p53 levels[J]. Molecular Carcinogenesis,2023.
DOI: http://dx.doi.org/10.26549/nrr.v3i2.17965
Refbacks
- 当前没有refback。
